3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Endometrial Neoplasms
6
Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
4
Colonic Neoplasms
4
Uterine Cervical Neoplasms
2
Neoplasm Metastasis
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Turcot syndrome
1
Triple Negative Breast Neoplasms
1
Sarcoma
1
Recurrence
1
Rectal Neoplasms
1
Rectal Adenocarcinoma with Mismatch-repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H)
1
Penile Neoplasms
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Ovarian Carcinosarcoma
1
Oropharyngeal Neoplasms
1
Neoplasms, Second Primary
1
Mouth Neoplasms
1
Locally Advanced Rectal Cancer (LARC)
1
Laryngeal Diseases
1
Hemangiosarcoma
1
Head and Neck Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Neuroendocrine
1
Interventions
pembrolizumab
2
lenvatinib
2
aldesleukin
2
Paclitaxel
2
Cisplatin
2
Carboplatin
2
Adoptive Transfer
2
trastuzumab deruxtecan
1
liposomal doxorubicin
1
fludarabine
1
dostarlimab
1
belzutifan
1
Vaccines, Synthetic
1
Therapeutic Touch
1
Taxes
1
Surveys and Questionnaires
1
Surgical Procedures, Operative
1
Standard of Care
1
Specimen Handling
1
Radiation
1
Practice Guidelines as Topic
1
Platinum
1
Papillomavirus Vaccines
1
Nivolumab
1
Nelfinavir
1
Imiquimod
1
Hysterectomy
1
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
1
Heavy Ion Radiotherapy
1
Gemcitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Vulvar Neoplasms
×
dostarlimab
×
Clear all
NCT06023862
2026-05-06
DOVE
Yonsei University
Phase 2
Recruiting
198 enrolled